세계의 간신증후군(HRS) 치료 시장 규모 : 치료법별, 유형별, 최종 사용자별, 지역 범위별 및 예측

Hepatorenal Syndrome Treatment Market Size And Forecast

Hepatorenal Syndrome Treatment Market size was valued at USD 11.95 Billion in 2024 and is projected to reach USD 17.4 Billion by 2032, growing at a CAGR of 4.81% from 2026 to 2032.

Global Hepatorenal Syndrome Treatment Market Drivers

The market drivers for the Hepatorenal Syndrome Treatment Market can be influenced by various factors. These may include:

Liver Disease Prevalence: Hepatorenal syndrome frequently develops as a side effect of more severe liver conditions like cirrhosis. Therefore, the need for HRS treatment is influenced by the occurrence of liver illnesses, such as cirrhosis.

Improvements in the Diagnosis and Treatment of Liver illnesses: Improvements in the management of liver illnesses, such as better cirrhosis and hepatitis treatment choices, can indirectly affect the incidence of HRS and increase demand for therapies.

Clinical Research and Development: Investigating the pathophysiology of HRS and creating innovative treatment modalities can spur market innovation. The market is growing as a result of clinical trials investigating novel medications, treatments, and treatment approaches.

Regulatory Environment: Market dynamics can be greatly impacted by regulatory authorization for novel medications or HRS treatment techniques. Regulations that are altered, such as those that expedite the review process for innovative medicines, could hasten the release of new medications.

Healthcare Infrastructure and Awareness: The demand for treatment is influenced by patients' and healthcare professionals' access to healthcare services as well as their knowledge of HRS. The market may grow as a result of upgrades to the healthcare system, especially in areas where liver disease prevalence is high.

Economic Factors: A number of economic factors influence market dynamics, including as healthcare spending, reimbursement practices, and insurance coverage for HRS treatment. Treatment accessibility and affordability have an impact on patient acceptance and market expansion.

Demographic Trends: The rising incidence of liver disorders and HRS is a result of both ageing populations and lifestyle choices. The need for HRS treatment is fueled by changes in demographics, such as the ageing of the population in wealthy nations.

Technological Innovations: New developments in organ support systems and better diagnostic methods for evaluating liver function can improve the management of hepatic failure and increase available therapeutic options.

Partnerships and Collaborations: The creation of novel HRS treatments is fueled by partnerships and collaborations among pharmaceutical companies, academic institutions, and healthcare organisations. In order to speed up the discovery of new drugs, partnerships can make it easier to share knowledge, assets, and intellectual property.

Global Hepatorenal Syndrome Treatment Market Restraints

Several factors can act as restraints or challenges for the Hepatorenal Syndrome Treatment Market. These may include:

restricted Therapy Alternatives: The current state of hepatorenal syndrome therapy alternatives is restricted in terms of effectiveness, which may impede market expansion.

Expensive Treatment: Liver transplantation is one of the more expensive forms of treatment for hepatorenal syndrome, which may prevent some patients from receiving therapy and impede market growth.

Regulatory Obstacles: Obstacles related to the approval procedures for novel treatments or therapies, in particular, might impede the expansion of the market.

Complexity of Diagnosis and Management: The diagnosis of hepatorenal syndrome can be challenging and necessitate specific knowledge, which can impede the start of treatment and hinder market expansion.

Limited Knowledge and Diagnosis: Patients' and healthcare providers' ignorance of hepatorenal syndrome can result in underdiagnosis and undertreatment, which would limit market expansion.

Comorbidities and Disease Complexity: Patients with cirrhosis or other underlying liver illnesses are frequently diagnosed with hemoptysis, which can complicate treatment plans and limit therapeutic options.

Healthcare Infrastructure: Hepatorenal syndrome therapy may be subpar in areas with poor access to specialized care facilities or a lack of suitable healthcare infrastructure, which would impede market growth.

Global Hepatorenal Syndrome Treatment Market Segmentation Analysis

The Global Hepatorenal Syndrome Treatment Market is segmented based on Treatment, Type, End-User, and Geography.

Hepatorenal Syndrome Treatment Market, By Treatment

• Therapeutics
• Surgical Treatment
• Based on Treatment, the market is segmented into Therapeutics and Surgical Treatment. Therapeutics constitute of using Terlivaz, Glypressin, Lucassin, and Hepatoren whereas surgical treatments, which have a higher market prevalence than Therapeutic treatment involve Liver Transplantation and Renal Replacement Therapy amongst others. The formulation of effective therapeutic drugs is still in its research stages

Hepatorenal Syndrome Treatment Market, By Type

• Type 1 Hepatorenal Syndrome
• Type 2 Hepatorenal Syndrome

Based on Type, The market is segmented into Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome. Type 1 HRS, which is a more acute and severe case is more prevalent than Type 2 HRS, which develops gradually.

Hepatorenal Syndrome Treatment Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Academic and Research Institutes
• Others

Based on End-User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Academic and Research Institutes, and Others. Hospitals are expected to retain a large share of the market at present and in the forecast period, due to well-established healthcare facilities around the globe supporting HRS surgical procedures.

Hepatorenal Syndrome Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Hepatorenal Syndrome Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Asia Pacific is expected to be the region with the most amount of Business in the forecast period, owing to the rapidly developing healthcare infrastructure and relatively economical surgical treatment procedures for Hepatorenal Syndrome.

Key Players

• The major players in the Hepatorenal Syndrome Treatment Market are:
• Cumberland Pharmaceuticals, Inc.
• Orphan Therapeutics, LLC.
• BioVie Inc.
• Mallinckrodt Pharmaceuticals
• Ikaria Inc., ESP Pharma Inc.
• Edwards Lifesciences Corporation
• Becton
• Dickinson and Company
• Fuji Systems Corp.
• Johnson & Johnson Co., and others.
• Ferring Pharmaceuticals
• Ocelot Bio Inc.
• Novartis

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, BY TREATMENT

• 5.1 Therapeutics
• 5.2 Surgical Treatment

6 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, BY TYPE

• 6.1 Type1 Hepatorenal Syndrome
• 6.2 Type 2 Hepatorenal Syndrome

7 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, BY END-USER

• 7.1 Hospitals
• 7.2 Ambulatory Surgical Centers
• 7.3 Academic and Research Institutes
• 7.4 Others

8 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Cumberland Pharmaceuticals, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Orphan Therapeutics, LLC.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 BioVie Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Mallinckrodt Pharmaceuticals
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Ikaria Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 ESP Pharma Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Edwards Lifesciences Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Becton, Dickinson and Company
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Fuji Systems Corp
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Johnson & Johnson Co.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research